This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritsche, T. R.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2005, p. 1468-1476, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1468-1476.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance

Thomas R. Fritsche,1* Helio S. Sader,1 Roy Cleeland,2 and Ronald N. Jones1,3

The JONES Group/JMI Laboratories, North Liberty, Iowa,1 Novartis Pharmaceuticals Corp., East Hanover, New Jersey,2 Tufts University School of Medicine, Boston, Massachusetts3

Received 16 December 2004/ Accepted 20 December 2004

LBM415 (NVP PDF-713) is the first member of the peptide deformylase (PDF) inhibitor class being developed for clinical trials as a parenteral and oral agent for treatment of community-acquired respiratory tract disease and serious infections caused by antimicrobial-resistant gram-positive cocci. In this study susceptibility testing results from 1,306 recent clinical isolates selected to overrepresent resistance trends among the species were summarized. All staphylococci (153 strains; MIC at which 90% of isolates were inhibited [MIC90], 2 µg/ml), Streptococcus pneumoniae (170 strains; MIC90, 1 µg/ml), other streptococci (150 strains; MIC90, 1 µg/ml), enterococci (104 strains; MIC90, 4 µg/ml), Moraxella catarrhalis (103 strains; MIC90, 0.5 µg/ml), and Legionella pneumophila (50 strains; MIC90, 0.12 µg/ml) were inhibited at ≤8 µg of LBM415/ml, as were 97% of Haemophilus influenzae isolates (300 strains; MIC90, 4 to 8 µg/ml). Among other bacterial groups, 100% of gram-positive and -negative anaerobes, including 22 Bacteroides spp. strains (31 strains total; MIC90, 1 µg/ml), were inhibited by ≤4 µg/ml, whereas Enterobacteriaceae (112 strains) and most nonfermentative bacilli (107 strains) were not inhibited at readily achievable concentrations. The compound was found to have a dominantly bacteriostatic action, and spontaneous single-step mutational rates occurred at low levels (10–6 to <10–8). Drug interaction studies failed to identify any class-specific synergistic interactions, nor were antagonistic interactions observed. Variations in broth and agar MIC test conditions demonstrated that, whereas the agar-based method trended towards a 1-log2 dilution-higher MIC than the broth method and was inoculum dependent, other variations in incubation environment, medium supplements, pH, or calcium concentration had little influence on LBM415 MIC results. Use of the efflux inhibitor phe-arg-ß-naphthylamide showed an average of 1 log2 dilution decrease in H. influenzae MICs, demonstrating the contribution of efflux pumps in influencing susceptibility to PDF inhibitors. The in vitro activity of LBM415 against targeted bacterial species, including resistant subsets, and other laboratory characteristics of this novel compound demonstrate the potential of PDF inhibitors as a new class of antimicrobial agents.

* Corresponding author. Mailing address: The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: thomas-fritsche{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, April 2005, p. 1468-1476, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1468-1476.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Caughlan, R. E., Sriram, S., Daigle, D. M., Woods, A. L., Buco, J., Peterson, R. L., Dzink-Fox, J., Walker, S., Dean, C. R. (2009). Fmt Bypass in Pseudomonas aeruginosa Causes Induction of MexXY Efflux Pump Expression. Antimicrob. Agents Chemother. 53: 5015-5021 [Abstract] [Full Text]  
  • Osborne, C. S., Neckermann, G., Fischer, E., Pecanka, R., Yu, D., Manni, K., Goldovitz, J., Amaral, K., Dzink-Fox, J., Ryder, N. S. (2009). In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models. Antimicrob. Agents Chemother. 53: 3777-3781 [Abstract] [Full Text]  
  • Dean, C. R., Narayan, S., Richards, J., Daigle, D. M., Esterow, S., Leeds, J. A., Kamp, H., Puyang, X., Wiedmann, B., Mueller, D., Voshol, H., van Oostrum, J., Wall, D., Koehn, J., Dzink-Fox, J., Ryder, N. S. (2007). Reduced Susceptibility of Haemophilus influenzae to the Peptide Deformylase Inhibitor LBM415 Can Result from Target Protein Overexpression Due to Amplified Chromosomal def Gene Copy Number. Antimicrob. Agents Chemother. 51: 1004-1010 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Credito, K. L., Pankuch, G. A., DeWasse, B., McGhee, P., Appelbaum, P. C. (2007). Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents. Antimicrob. Agents Chemother. 51: 770-773 [Abstract] [Full Text]  
  • Bogdanovich, T., Smith, K. A., Clark, C., Pankuch, G. A., Lin, G., McGhee, P., Dewasse, B., Appelbaum, P. C. (2006). Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species.. Antimicrob. Agents Chemother. 50: 2323-2329 [Abstract] [Full Text]  
  • Huang, J., Van Aller, G. S., Taylor, A. N., Kerrigan, J. J., Liu, W.-S., Trulli, J. M., Lai, Z., Holmes, D., Aubart, K. M., Brown, J. R., Zalacain, M. (2006). Phylogenomic and Biochemical Characterization of Three Legionella pneumophila Polypeptide Deformylases.. J. Bacteriol. 188: 5249-5257 [Abstract] [Full Text]  
  • Wang, W., White, R., Yuan, Z. (2006). Proteomic Study of Peptide Deformylase Inhibition in Streptococcus pneumoniae and Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 1656-1663 [Abstract] [Full Text]  
  • Watters, A. A., Jones, R. N., Leeds, J. A., Denys, G., Sader, H. S., Fritsche, T. R. (2006). Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother 57: 914-923 [Abstract] [Full Text]  
  • Fieulaine, S., Juillan-Binard, C., Serero, A., Dardel, F., Giglione, C., Meinnel, T., Ferrer, J.-L. (2005). The Crystal Structure of Mitochondrial (Type 1A) Peptide Deformylase Provides Clear Guidelines for the Design of Inhibitors Specific for the Bacterial Forms. J. Biol. Chem. 280: 42315-42324 [Abstract] [Full Text]  
  • Zhou, Z., Song, X., Gong, W. (2005). Novel Conformational States of Peptide Deformylase from Pathogenic Bacterium Leptospira interrogans: IMPLICATIONS FOR POPULATION SHIFT. J. Biol. Chem. 280: 42391-42396 [Abstract] [Full Text]  
  • Dean, C. R., Narayan, S., Daigle, D. M., Dzink-Fox, J. L., Puyang, X., Bracken, K. R., Dean, K. E., Weidmann, B., Yuan, Z., Jain, R., Ryder, N. S. (2005). Role of the AcrAB-TolC Efflux Pump in Determining Susceptibility of Haemophilus influenzae to the Novel Peptide Deformylase Inhibitor LBM415. Antimicrob. Agents Chemother. 49: 3129-3135 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»